Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Neuer Gesetzesentwurf!: Kommt nach der Cannabis-Neuregulierung nun eine komplette Legalisierung in USA?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
120 Leser
Artikel bewerten:
(0)

Global Intravenous Immunoglobulin (IGM, IGG, IGE, Immunoglobulin D (IGD) and IGA) Market, 2025

DUBLIN, November 9, 2017 /PRNewswire/ --

The "Global Intravenous Immunoglobulin Market Analysis & Trends - Industry Forecast to 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The Intravenous Immunoglobulin market is poised to grow strong during the forecast period 2017 to 2025

Some of the prominent trends that the market is witnessing include improving health care infrastructure across the globe, increasing number of chronic inflammatory demyelinating polyneuropathy (CIDP) patients and technological developments in the methods used for production and purification of IVIG products.

Based on therapeutic area the market is categorized into acute infections, immune deficiencies and autoimmune diseases. Furthermore Immune Deficiencies are divided into x-linked agammaglobulinemia, acquired compromised immunity conditions and hypogammaglobulinemia (primary immune deficiencies). Autoimmune Diseases are segmented into inflammatory diseases and immune thrombocytopenia (ITP).

Depending on product types the market is segregated by IGM, IGG, IGE, Immunoglobulin D (IGD) and IGA.

On the basis of plasma protein the market is bifurcated into albumin, factor IX, polyvalent IVIG, hyperimmunes (IM&IV) and factor VIII.

In terms of end user the market is segmented into home care, hospitals and clinics.

By application the market is classified into primary humoral immunodeficiency, immunodeficiency diseases, myasthenia gravis, hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), inflammatory myopathies, kawasaki disease, idiopathic thrombocytopenic purpura (ITP), guillain-barre syndrome (GBS), chronic lymphocytic leukemia, specific antibody deficiency (SAD), multifocal motor neuropathy, congenital AIDS and other applications.

Key Topics Covered:

1 Market Outline

2 Executive Summary

3 Market Overview

4 Global Intravenous Immunoglobulin Market, By Therapeutic Area

5 Global Intravenous Immunoglobulin Market, By Product Type

6 Global Intravenous Immunoglobulin Market, By Plasma Protein

7 Global Intravenous Immunoglobulin Market, By End User

8 Global Intravenous Immunoglobulin Market, By Application

9 Global Intravenous Immunoglobulin Market, By Geography

10 Key Player Activities

11 Leading Companies

  • Biotest AG
  • Guizhou Taibang Biological Products Co.
  • Baxter International Inc
  • China Biologic Products, Inc
  • Shanghai RAAS Blood Products Co., Ltd
  • Grifols, S.A
  • Beijing Tiantan Biological Products Co., Ltd
  • Octapharma AG
  • CSL Limited
  • Hualan Biological Engineering Inc
  • Kedrion Biopharma
  • Biotest AG
  • OMRIX Biopharmaceuticals Ltd
  • LFB BIOTECHNOLOGIES
  • BDI Pharma Inc

For more information about this report visit https://www.researchandmarkets.com/research/96kh5x/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.